[go: up one dir, main page]

WO2001091798A3 - Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers - Google Patents

Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers Download PDF

Info

Publication number
WO2001091798A3
WO2001091798A3 PCT/EP2001/006106 EP0106106W WO0191798A3 WO 2001091798 A3 WO2001091798 A3 WO 2001091798A3 EP 0106106 W EP0106106 W EP 0106106W WO 0191798 A3 WO0191798 A3 WO 0191798A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrug compounds
activated prodrug
methods
biologically active
tumor activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/006106
Other languages
English (en)
Other versions
WO2001091798A2 (fr
Inventor
Andre Trouet
Vincent Dubois
Arnold Oronsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Priority to CA002408103A priority Critical patent/CA2408103A1/fr
Priority to AU2001279630A priority patent/AU2001279630A1/en
Priority to JP2001587810A priority patent/JP2003534387A/ja
Priority to US10/296,954 priority patent/US20040014652A1/en
Priority to EP01957808A priority patent/EP1286700A2/fr
Publication of WO2001091798A2 publication Critical patent/WO2001091798A2/fr
Anticipated expiration legal-status Critical
Publication of WO2001091798A3 publication Critical patent/WO2001091798A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de promédicaments, des compositions renfermant les composés de promédicaments précités, des procédés de fabrication des composés de promédicaments précités et des procédés d'utilisation de ces derniers. Les composés de promédicaments de l'invention comprennent une entité biologiquement active liée à un fragment masquant via un fragment de liaison. Les composés de promédicaments de l'invention sont sélectivement activés sur les cellules cibles ou à proximité de celles-ci et ils présentent une toxicité inférieure et, éventuellement, une demi-vie sérique ou in vivo plus longue que l'entité biologiquement active correspondante pure.
PCT/EP2001/006106 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers Ceased WO2001091798A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002408103A CA2408103A1 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
AU2001279630A AU2001279630A1 (en) 2000-06-01 2001-05-29 Tumor activated prodrug compounds
JP2001587810A JP2003534387A (ja) 2000-06-01 2001-05-29 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法
US10/296,954 US20040014652A1 (en) 2000-06-01 2001-05-29 Tumor activated prodrug compounds and methods of making and using the same
EP01957808A EP1286700A2 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US20899600P 2000-06-01 2000-06-01
EP00870130.2 2000-06-01
US60/208,996 2000-06-01
EP00870130 2000-06-15
EP00870306 2000-12-18
EP00870306.8 2000-12-18
EP01957808A EP1286700A2 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers

Publications (2)

Publication Number Publication Date
WO2001091798A2 WO2001091798A2 (fr) 2001-12-06
WO2001091798A3 true WO2001091798A3 (fr) 2002-12-05

Family

ID=27440072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/006106 Ceased WO2001091798A2 (fr) 2000-06-01 2001-05-29 Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers

Country Status (2)

Country Link
EP (1) EP1286700A2 (fr)
WO (1) WO2001091798A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US12502439B2 (en) 2012-04-27 2025-12-23 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
IL150992A0 (en) * 2000-02-24 2003-02-12 Genentech Inc Caspase activated prodrugs therapy
CA2423850C (fr) 2000-10-09 2017-07-04 Isis Innovation Limited Anticorps therapeutiques
CA2436830A1 (fr) * 2000-11-06 2002-06-20 Asilomar Pharmaceuticals, Inc. Composes pour administration intracellulaire de fractions therapeutiques a des cellules nerveuses
US20040097586A1 (en) * 2001-01-30 2004-05-20 Andre Trouet Anti-tumor compounds
KR100468316B1 (ko) * 2002-01-29 2005-01-27 주식회사 웰진 Ｄｎａ의 세포 또는 조직 내 전달 효율을 높이는 펩타이드
JP4699755B2 (ja) * 2002-08-23 2011-06-15 ガブリエル ムルソフ， 腫瘍細胞におけるアポトーシスのＨｓｐ７０／Ｈｓｐ７０ペプチド依存性誘導物質としてのグランザイムＢの使用
US20050043215A1 (en) * 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
FR2858936A1 (fr) * 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
EP1765403A4 (fr) * 2004-05-10 2011-03-30 Univ Utah Res Found Ciblage actif et passif combines d'agents biologiquement actifs
EP1674113A1 (fr) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
US7214767B2 (en) * 2005-05-25 2007-05-08 Hiroshi Kanno VHL peptide
CA2626356C (fr) * 2005-10-21 2017-08-22 Catalyst Biosciences, Inc. Proteases modifiees qui inhibent l'activation du complement
US20090220529A1 (en) * 2006-03-10 2009-09-03 Diatos, S.A. Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker
MX2009001691A (es) 2006-08-31 2009-02-25 Hoffmann La Roche Metodo para produccion del factor de crecimiento i tipo insulina.
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
US9624309B2 (en) 2007-08-15 2017-04-18 Bayer Intellectual Property Gmbh Monospecific and multispecific antibodies and method of use
AU2016213702C1 (en) * 2007-08-22 2018-11-29 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
AU2013202755B2 (en) * 2007-08-22 2016-05-12 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
EP2385955B1 (fr) * 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Compositions d anticorps modifiées et leurs procédés de production et d utilisation
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
BRPI1011384A2 (pt) 2009-02-23 2016-03-15 Cytomx Therapeutics Inc pro-proteinas e seus metodos de uso
WO2013192546A1 (fr) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Anticorps activables ayant des fragments stériques ne se liant pas et leurs procédés d'utilisation
PE20150643A1 (es) 2012-06-22 2015-05-29 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos
WO2014052462A2 (fr) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Anticorps activables qui se lient au récepteur d'interleukine-6 et procédés d'utilisation de ces derniers
CA2896282C (fr) 2013-01-04 2021-07-20 Cytomx Therapeutics, Inc. Compositions et procedes de detection d'une activite protease dans des systemes biologiques
KR20160018579A (ko) * 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
JP2016537685A (ja) * 2013-09-12 2016-12-01 ディーエスエム アイピー アセッツ ビー．ブイ． 眼球デバイス
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (fr) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Anticorps qui se lient à des anticorps activables et leurs procédés d'utilisation
ES2932777T3 (es) 2014-01-31 2023-01-25 Cytomx Therapeutics Inc Sustratos de matriptasa y activador del plasminógeno-u y otros motivos escindibles y métodos de uso de los mismos
WO2016014974A2 (fr) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding antibodies against PDL1 and methods for their preparation
US10745481B2 (en) 2015-05-04 2020-08-18 Cytomx Therapeutics, Inc. Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
ES2910407T3 (es) 2015-05-04 2022-05-12 Cytomx Therapeutics Inc Anticuerpos anti-CD71 activables y procedimientos de uso de los mismos
CA2984892A1 (fr) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anticorps anti-itga3, anticorps anti-itga3 activables, et leurs methodes d'utilisation
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
JP7039582B2 (ja) 2016-11-03 2022-03-22 ブリストル－マイヤーズ スクイブ カンパニー 活性化可能な抗ｃｔｌａ－４抗体およびその使用
EA201991353A1 (ru) 2016-12-09 2019-11-29 Двухвалентные антитела, маскированные спирализованными спиралями
EP3630838A1 (fr) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Anticorps anti-pdl1 activables, et leurs procédés d'utilisation
KR20200031113A (ko) 2017-07-20 2020-03-23 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 항체의 특성을 정성적 및/또는 정량적으로 분석하는 방법 및 이의 용도
EP3694885A1 (fr) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs procédés d'utilisation
EP3823674A4 (fr) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. Conjugués pour administrer un agent anticancéreux à des cellules nerveuses, méthodes d'utilisation et leurs procédés de fabrication
KR20210102318A (ko) 2018-12-06 2021-08-19 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이스-절단성 기질 및 세린 또는 시스테인 프로테이스-절단성 기질 그리고 이들의 사용 방법
AU2021254279A1 (en) 2020-04-09 2022-11-10 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique
CA3211924A1 (fr) 2021-03-16 2022-09-22 Sayantan Mitra Constructions de cytokines activables masquees et methodes et compositions associees

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005863A1 (fr) * 1994-08-19 1996-02-29 La Region Wallonne Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005863A1 (fr) * 1994-08-19 1996-02-29 La Region Wallonne Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CALICETI P ET AL: "PREPARATION AND PROPERTIES OF MONOMETHOXY POLY(ETHYLENE GLYCOL) DOXORUBICIN CONJUGATES LINKED BY AN AMINO ACID OR A PEPTIDE AS SPACER", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 48, no. 7, 1 July 1993 (1993-07-01), pages 919 - 932, XP000371926, ISSN: 0014-827X *
CHARI R.V.J.: "Targeted delivery of chemotherapeutics: Tumor - activated prodrug therapy.", ADVANCED DRUG DELIVERY REVIEWS, (6 APR 1998) 31/1-2 (89-104)., XP002204748 *
CHARI, R. V. J. (1) ET AL: "Integration of SB-408075 into combination treatments of human colon xenograft models of SCID mice.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2000) NO. 41, PP. 291. MEETING INFO.: 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CALIFORNIA, USA APRIL 01-05, 2000, XP002204745 *
CHARI, R. V. J. ET AL: "C242-DM1: A tumor - activated prodrug that shows exceptional activity in human colon tumor xenograft models at non-toxic doses.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 643. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002204746 *
LAMBERT, J. M. ET AL: "Pharmacokinetics, in vivo stability, and toxicity of the tumor - activated prodrug, C242-DM1, a novel colorectal cancer agent.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 522. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002204747 *
NICHIFOR, MARIETA ET AL: "Macromolecular prodrugs of 5-fluorouracil. 2: Enzymic degradation", J. CONTROLLED RELEASE (1996), 39(1), 79-92, XP002204749 *
TROUET A ET AL: "Extracellularly tumor - activated prodrugs fo the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.", CANCER RESEARCH, (2001 APR 1) 61 (7) 2843-6., XP002204750 *
TROUET, ANDRE (1) ET AL: "CPI-0004Na: An extracellularly tumor - activated prodrug of doxorubicin.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2000) NO. 41, PP. 522. MEETING INFO.: 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CALIFORNIA, USA APRIL 01-05, 2000, XP002204744 *
WIEBE, L. I. ET AL: "Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection", ADVANCED DRUG DELIVERY REVIEWS (1999), 39(1-3), 63-80, XP002204743 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169321B2 (en) 2007-08-22 2015-10-27 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US12502439B2 (en) 2012-04-27 2025-12-23 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

Also Published As

Publication number Publication date
WO2001091798A2 (fr) 2001-12-06
EP1286700A2 (fr) 2003-03-05

Similar Documents

Publication Publication Date Title
WO2001091798A3 (fr) Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
PT1157037E (pt) Conjugados de gcsf
WO2004108070A3 (fr) Conjugues polymeres liberables fondes sur des lieurs biodegradables aliphatiques
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
DE69531342D1 (de) Avidin-biotin immunokonjugate
WO1999042080A3 (fr) Compositions durcissables avec des proprietes antimicrobinnes
DZ2646A1 (fr) Dérivés de thiénopyrimidine et thiénopyridine utiles comme agents anticancéreux et compositions les contenant.
DK1075282T3 (da) PEG-LHRH-analog-konjugater
AU7931301A (en) Method of using diketopiperazines and composition containing them
BG104819A (en) Substituted indolealkanoic acids
WO2000066104A3 (fr) Composes inhibant ace-2 et leurs procedes d'utilisation
WO2000018439A3 (fr) Utilisation de marqueurs de neoangiogenese pour diagnostiquer et traiter des tumeurs
PT1140808E (pt) Formulacoes de pesticidas contendo tensioactivos de ester de hemissulfato de tristirilfenol alcoxilado, neutralizados com amina alcoxilada
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
WO2002059368A8 (fr) Expression specifique de la mucine utilisee comme marqueur du cancer pancreatique
AU5622300A (en) Stable l-ascorbic acid composition
WO2004112717A3 (fr) Conjugue destine au ciblage specifique d'agents anticancereux sur des cellules cancereuses, et production du conjugue
WO2000053231A3 (fr) Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes
WO2001042792A3 (fr) Compositions, kits, et methodes d'identification, d'evaluation, de prevention, et de therapie du cancer du col de l'uterus
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
AU2002214876A1 (en) Combination preparation of a biological response modifier and an anticancer agent and uses thereof
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores
WO2000072802A3 (fr) Composes hydrosolubles multi-biotine
EP1011329A4 (fr) Paclitaxels 7-methylthiooxomethyle et 7-methylthiodioxomethyle
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2408103

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 587810

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001957808

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001957808

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10296954

Country of ref document: US